Core Viewpoint - The stock of Brainstorm Cell Therapeutics Inc. (脑动极光-B) experienced a significant increase of nearly 10%, reaching a peak price of 8.14 HKD per share, with a total market capitalization of approximately 10 billion HKD as of January 8, 2026 [1][2]. Group 1: Stock Performance - The stock opened at 7.46 HKD and reached a maximum price of 8.14 HKD, with a closing price of 7.21 HKD the previous day [2]. - The stock's 52-week high is 17.79 HKD, while the 52-week low is 3.51 HKD [2]. - The trading volume was 39.6 million shares, with an external trading volume of 22.58 million and an internal trading volume of 17.02 million [2]. Group 2: Company Developments - Brainstorm Cell Therapeutics announced on January 7 that it has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2]. - The company, in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has received approval to establish the "Beijing Key Laboratory for Precision Intelligent Diagnosis and Treatment of Mental Disorders" [1][2].

Core Viewpoint - The company, Brainstorm Aurora-B (06681), has signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Business Developments - The company’s stock price increased by 8.46%, currently trading at 7.82 HKD with a transaction volume of 149 million HKD [1][4]. - The collaboration with Peking University Sixth Hospital and Shandong Mental Health Center aims to enhance the development of mental health digital therapy products [1][4]. - The company has also received approval to establish the "Precision Intelligent Diagnosis and Treatment Innovation and Transformation Key Laboratory for Mental Disorders" in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering [1][4]. Group 2: Strategic Partnerships - The company has formed a close commercial partnership with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disorders, to promote the clinical application of mental health digital therapy products [1][4]. - The recent partnerships expand the company's network within core mental health specialty hospitals across the country, creating a comprehensive commercial implementation network from national flagship centers to regional hubs and key specialty hospitals [1][4].

Core Viewpoint - The company, Brainstorm Cell Therapeutics-B (06681), has seen its stock price increase by over 8%, currently trading at 7.75 HKD with a transaction volume of 58.17 million HKD, following the announcement of significant business collaborations aimed at advancing digital therapies for mental health [1] Group 1: Business Collaborations - The company has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to jointly promote the research and commercialization of digital therapy products for mental health [1] - The collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University has led to the establishment of a key laboratory for precision intelligent diagnosis and treatment of mental disorders in Beijing [1] Group 2: Clinical Applications and Network Expansion - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disease medicine, to promote the clinical application of digital therapy products for mental health [1] - The recent partnerships further expand the company's presence in core mental health specialty hospitals across the country, creating a comprehensive commercial network from national flagship centers to regional hubs and key specialty hospitals [1]

Core Viewpoint - The company, Brainstorm Aurora-B (06681), has seen its stock price increase by over 8%, currently trading at 7.75 HKD with a transaction volume of 58.17 million HKD, following the announcement of significant business collaborations aimed at advancing digital therapies for mental health [1] Group 1: Business Collaborations - The company has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to jointly promote the research and commercialization of digital therapy products for mental health [1] - The collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University has led to the establishment of a key laboratory for precision intelligent diagnosis and treatment of mental disorders in Beijing [1] Group 2: Clinical Applications and Network Expansion - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disorders, to promote the clinical application of digital therapy products for mental health [1] - The recent partnerships further expand the company's presence in core mental health specialty hospitals across the country, creating a comprehensive commercial network from national flagship centers to regional hubs and key specialty hospitals [1]

Group 1 - The core point of the article highlights that Brainstorm Aurora-B (06681) has deposited shares worth HKD 1.959 billion into Guotai Junan (Hong Kong), representing 20.77% of the total shareholding [2] Group 2 - Brainstorm Aurora has recently signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [3] - The company, in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has successfully applied for the establishment of the "Beijing Key Laboratory for Precision Intelligent Diagnosis and Treatment of Mental Disorders" [3]

Group 1 - The core viewpoint of the article highlights that Brainstorm Aurora-B (06681) has deposited shares worth HKD 1.959 billion into Guotai Junan (Hong Kong), representing 20.77% of the total shareholding [1] - The company has recently signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1] - Additionally, the joint application for the "Precision Intelligent Diagnosis and Treatment Innovation and Transformation Key Laboratory for Mental Disorders" with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering has been officially approved for establishment [1]

Core Viewpoint - The company has signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Collaboration Details - The collaboration with Peking University Sixth Hospital includes the development of digital therapies and clinical application research, focusing on ADHD cognitive digital therapy effectiveness and a precision intelligent diagnosis system for depression [2]. - The research scope encompasses developing digital therapy products for emotional and behavioral issues across the entire lifecycle, including clinical validation of cognitive digital therapies aimed at improving learning abilities in children with ADHD [2]. - The partnership with Shandong Provincial Mental Health Center involves developing cognitive screening and intervention systems for mental disorders, as well as methods for capacity training guided by virtual humans [3]. Group 2: Laboratory Establishment - The "Precision Intelligent Diagnosis and Innovation Transformation Key Laboratory for Mental Diseases" has been officially approved, with the company as a core co-construction unit alongside Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering [3]. - The laboratory will focus on innovation and transformation driven by clinical needs in mental health, integrating clinical medicine, basic research, technology development, and hardware innovation [3]. Group 3: Strategic Positioning - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health facility, to promote the clinical application of digital mental health therapies [4]. - The recent collaborations expand the company's network across key mental health hospitals in China, creating a comprehensive commercial landing network from national flagship centers to regional hubs and specialized hospitals [4]. - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the digital mental health therapy field, accelerating product development and commercialization [4].

Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2][3]. Group 1: Joint Research Content - The research will focus on developing digital therapies and clinical applications, including the effectiveness of cognitive digital therapies for Attention Deficit Hyperactivity Disorder (ADHD) and a precision intelligent diagnosis system for depression [2]. - The research scope includes developing digital therapy products for emotional and behavioral issues across the entire lifecycle, with clinical validation for various age groups [2][3]. Group 2: Commercial Cooperation Content - The company will collaborate on digital technology services for cognitive disorder diagnosis and treatment, establishing a health management system covering elderly, children, and adults [2][3]. Group 3: Establishment of Key Laboratory - The "Beijing Key Laboratory for Precision Intelligent Diagnosis and Transformation of Mental Disorders" has been officially approved, with the company as a core co-builder [4]. - The laboratory will focus on innovation and transformation driven by clinical needs, integrating clinical medicine, basic research, technology development, and hardware innovation [4]. Group 4: Strategic Importance - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the field of digital mental health therapies, accelerating product development and commercialization [5]. - The company aims to continue partnerships with top medical institutions to build a nationwide integrated digital mental health service system [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 及 獲批精神疾病精準智能診療創新轉化北京市重點實驗室 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司近期與北京大學第六醫院及山東省 精神衛生中心（統稱「合作方」）分別簽訂重要業務合作協議（統稱「業務合作協 議」），共同推進精神健康數字療法產品的研發與商業化。此外，本公司與北京大 學第六醫院、北京大學軟件工程國家工程研究中心聯合申報的「精神疾病精準智 能診療創新轉化北京市重點實驗室」（「實驗室」）已正式獲准組建。 一、與北京大學第六醫院簽訂業務合作協議 1. 聯合研發內容 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 簽訂重要業務合作協議 研究內 ...